⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754860 | 0.77 | GPR3 (0.32) | — | |
| SCHEMBL3764212 | 0.74 | GALR1 (0.33) | — | |
| SCHEMBL2589655 | 0.72 | CD44 (0.45) | — | |
| Hydrochloric Acid SCHEMBL5849050 | 0.70 | CD44 (0.44) | — | |
| SCHEMBL31332380 | 0.68 | SLC40A1 (0.31) | — | |
| SCHEMBL28445860 | 0.67 | PNMT (0.49) | — | |
| SCHEMBL145412 | 0.66 | PNMT (0.52) | — | |
| SCHEMBL519189 | 0.66 | RYR2 (0.53) | — | |
| SCHEMBL4839624 | 0.65 | — | — | |
| SCHEMBL25204291 | 0.63 | PNMT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149992-A1 | IMAGING COMPOUNDS FOR DETECTING OR IMAGING SENESCENT CELLS | UNIVERSITY OF DUNDEE (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-11969473-B2 | Multifunctional conjugates | E.P.O.S IASIS RESEARCH AND DEVELOPMENT LIMITED (CY) | 2024-04-30 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| WO-2024003557-A1 | SULFOXIMINES AS INHIBITORS OF LYSYL OXIDASE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| EP-2516449-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON INC. (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012125603-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011087822-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |